<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sulfatide is a <z:chebi fb="0" ids="24402">glycosphingolipid</z:chebi> known to interact with several extracellular matrix proteins, such as tenascin-C which is overexpressed in many types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> including that of the colon </plain></SENT>
<SENT sid="1" pm="."><plain>In view of the limited success of chemotherapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and high toxicity of <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (DOX), a sulfatide-containing liposome (SCL) encapsulation approach was taken to overcome these barriers </plain></SENT>
<SENT sid="2" pm="."><plain>This study assessed the in vitro cytotoxicity, biodistribution, therapeutic efficacy and systemic toxicity in vivo of sulfatide-containing liposomal <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (SCL-DOX) using human <z:mp ids='MP_0009314'>colonic adenocarcinoma</z:mp> HT-29 xenograft as the experimental model </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro, SCL-DOX was shown to be delivered into the nuclei and displayed prolonged retention compared with the free DOX </plain></SENT>
<SENT sid="4" pm="."><plain>The use of this nanodrug delivery system to deliver DOX for treatment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice produced a much improved therapeutic efficacy in terms of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> suppression and extended survival in contrast to the free drug </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, treatment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice with SCL-DOX resulted in a lower DOX uptake in the principal sites of toxicity of the free drug, namely the heart and skin, as well as reduced <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> and diminished cardiotoxicity </plain></SENT>
<SENT sid="6" pm="."><plain>Such natural <z:chebi fb="23" ids="18059">lipid</z:chebi>-guided nanodrug delivery systems may represent a new strategy for the development of effective anticancer chemotherapeutics targeting the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment for both <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and micrometastases </plain></SENT>
</text></document>